Studies immune cells in psoriasis patients treated with deucravacitinib
Examines immune cells in skin and blood of adults with psoriasis taking deucravacitinib.
Plain-language title generated from the registry record
Registry title: Correction of Psoriatic T Cell Signatures by Deucravacitinib
Key facts
- Where
- San Francisco, United StatesSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT05858645, who can take part
Where in United States
- University of California San FranciscoSan Francisco, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of California, San Francisco
- Trial code
- NCT05858645
- Record updated
- 4 June 2026
- Original description
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.Read full original descriptionShow less
Correction of Psoriatic T Cell Signatures by Deucravacitinib
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.
Inclusion: 18 years of age or older; Patients with moderate-severe psoriasis (BSA >= 10%, PASI >=12, static Physician's Global Assessment (sPGA) 3 and above).
Exclusion: tuberculosis or other active serious infection; active systemic malignancy; Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data; taking systemic immunosuppressives in the last 12 weeks; pregnancy; severe immunodeficiency (either from genetic or infectious causes); breast-feeding.